<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02249715</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-1293-14-OC-CTIL</org_study_id>
    <nct_id>NCT02249715</nct_id>
  </id_info>
  <brief_title>Development of a Monitoring Set-up and Algorithm Using Functional MRI (fMRI) and EEG for Prediction of Response to Repetitive Deep Transcranial Magnetic Stimulation (rDTMS) for Patients With Parkinson's Disease</brief_title>
  <official_title>Pilot Study for Development of a Monitoring Set-up and Algorithm Using Functional MRI (fMRI) and EEG for Prediction of Response to Repetitive Deep Transcranial Magnetic Stimulation (rDTMS) for Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brainsway</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ElMindA Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To characterize physiological biomarkers of positive response to rDTMS using EEG and&#xD;
           functional MRI (fMRI) in patients with PD.&#xD;
&#xD;
        -  To develop a set-up and algorithm for neurophysiological monitoring for PD patients&#xD;
           using EEG and fMRI in patients treated by rDTMS.&#xD;
&#xD;
        -  To integrate rDTMS stimulation with monitoring techniques with the ultimate goal of&#xD;
           providing closed-loop feedback where monitoring informs the stimulation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PD Patients aged 40 years or older, diagnosed as idiopathic PD according to the UK Brain Bank&#xD;
      criteria will be treated by an established rDTMS protocol will be monitored before, during&#xD;
      and after rDTMS using quantitative EEG and brain network analysis and fMRI while performing a&#xD;
      series of cognitive and motor tasks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS)</measure>
    <time_frame>3 month</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Parkinson</condition>
  <arm_group>
    <arm_group_label>rDTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Brainsway Multiway deep TMS device (two channels)</intervention_name>
    <arm_group_label>rDTMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Idiopathic PD patients aged 40-75 years;&#xD;
&#xD;
          2. Hoehn and Yahr stages II to IV&#xD;
&#xD;
          3. Patients on stable antiparkinsonian therapy for 1 month&#xD;
&#xD;
          4. Right hand dominance with right afflicted side.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in current clinical study or clinical study within 30 days prior to this&#xD;
             study.&#xD;
&#xD;
          2. Subject has an atypical parkinsonian syndrome or secondary parkinsonism (e.g., due to&#xD;
             drugs, metabolic neurogenetic disorders, encephalitis, cerebrovascular disease or&#xD;
             other degenerative disease)&#xD;
&#xD;
          3. Patients with significant psychiatric symptoms or history.&#xD;
&#xD;
          4. Patients with psychotic symptoms or active depressive symptoms&#xD;
&#xD;
          5. Treatment with neuroleptics.&#xD;
&#xD;
          6. Beck depression inventory (BDI) score &lt;14&#xD;
&#xD;
          7. Mini Mental status examination (MMSE) score &lt;25&#xD;
&#xD;
          8. History of migraine or frequent or severe headaches.&#xD;
&#xD;
          9. Significant sensory deficits, e.g., deafness or blindness History of head injury or&#xD;
             neurosurgical interventions.&#xD;
&#xD;
         10. Subjects who have concomitant epilepsy, a history of seizure/s, heat convulsions or&#xD;
             history of epilepsy in first degree relative.&#xD;
&#xD;
         11. History of any metal in the head (outside the mouth).&#xD;
&#xD;
         12. The presence of cochlear implants&#xD;
&#xD;
         13. Known history of any metallic particles in the eye, implanted cardiac pacemaker,&#xD;
             implanted neurostimulators, surgical clips (above the shoulder line) or any medical&#xD;
             pumps.&#xD;
&#xD;
         14. Subjects with an unstable medical disorder.&#xD;
&#xD;
         15. Current drug abuse (including Cannabis) or alcoholism.&#xD;
&#xD;
         16. Pregnancy or not using a reliable method of birth control.&#xD;
&#xD;
         17. Patients with severe tremor or dyskinesia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oren Cohen, M.D</last_name>
    <phone>972-3-5305296</phone>
    <email>Oren.Cohen@sheba.health.gov.il</email>
  </overall_contact>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>September 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2014</study_first_posted>
  <last_update_submitted>September 23, 2014</last_update_submitted>
  <last_update_submitted_qc>September 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson</keyword>
  <keyword>TMS</keyword>
  <keyword>BNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

